All News

Oncologist Who Specializes in Treating Rare Blood Cancers ‘Learns from Patients Every Day’

July 15th 2022

An expert from the Tisch Cancer Institute discusses how he learns from patients and their caregivers, and how their insight has helped lead advancements in the treatment of myeloproliferative neoplasms, a group of rare blood cancers.

Trial Launched to Analyze Safety of Novel Drug to Treat Severe Side Effect that Occurs in Approximately Half of Patients With Advanced Cancer

July 15th 2022

The first patient enrolled onto a phase 1 trial has received TCMB07, an investigational drug, for the treatment of cachexia, a severe disorder that may occur in more than half of patients with advanced-stage cancer.

Backtracking Is Allowed in Cancer Care

July 15th 2022

If I make a wrong turn while hiking, I backtrack until I find my way again. I’ve decided that it’s OK to do the same thing when it comes to finding a cancer care team.

FDA Fast Tracks Investigational Drug for the Treatment of Recurrent Brain Cancer

July 15th 2022

The safety, optimal dosage and efficacy of the investigational drug is currently being evaluated in a first-in-human trial in patients with recurrent high-grade glioblastoma, a type of spinal cord and brain cancer.

Educated Patient® Skin Cancer Summit Integrative Care Presentation: June 18, 2022

July 15th 2022

Watch Lorenzo G. Cohen, from The University of Texas MD Anderson Cancer Center, discuss integrative care during the CURE Educated Patient Skin Cancer Summit.

FDA Lifts Hold on Trial Investigating Novel Drug in Patients With High-Risk Breast Cancer

July 14th 2022

The FDA has permitted the manufacturer of a novel drug to continue a phase 3 clinical trial investigating the effects of treatment with a novel drug in patients with HER2/neu-positive primary breast cancer.

Cabometyx-Tecentriq Combo Bests Nexavar in Controlling Disease, Limiting Progression in Patients With Advanced Liver Cancer

July 14th 2022

Treatment with Cabometyx in combination with Tecentriq induced superior progression-free survival outcomes and disease control rates versus Nexavar alone in patients with advanced hepatocellular carcinoma, the most common type of liver cancer.

I Have the Best of Both Worlds: A Local Cancer Center and a Research Center

July 14th 2022

The decision to be treated locally or at a large research center can be a difficult one, but I am lucky enough to have both.

Amazon and Fred Hutch Partner to Investigate Safety, Efficacy of Cancer Vaccine

July 14th 2022

Amazon and Fred Hutchinson Cancer Center recently launched an early-phase clinical trial to assess the safety and efficacy of a cancer vaccine in the treatment of patients with late-stage skin cancer or hormone receptor-positive, HER2-negative breast cancer.

Educated Patient® Skin Cancer Summit Basics of Immunotherapy Presentation: June 18, 2022

July 14th 2022

Watch Dr. Jedd D. Wolchok, from Memorial Sloan Kettering Cancer Center, discuss immunotherapy, during the CURE Educated Patient Skin Cancer Summit.

Trial Launched to Investigate Novel Triplet Therapy in Treatment of Rare Gastric or Esophageal Cancer

July 13th 2022

The manufacturer of one of the cancer treatments announced that it is also participating in clinical trials assessing the safety and efficacy of their product in colorectal and endometrial cancer.

Sometimes the Reality of Cancer Gets Lost in Translation

July 13th 2022

When a friend with metastatic breast cancer said that her cancer responded to treatment and she was excited to stop taking daily pills, I thought that something must have been miscommunicated to her.

Patients With Advanced Pancreatic Cancer Derive Benefit From Chemo-Free Treatment Regimen

July 13th 2022

The use of a chemotherapy-free, combination regimen as a maintenance treatment option was associated with an improvement in survival in a group of patients with advanced pancreatic cancer.

Educated Patient® Skin Cancer Summit Multidisciplinary Approach Panel: June 18, 2022

July 13th 2022

Watch Dr. Sherrif Ibrahim, Dr. Erica B. Friedman and Dr. Nicholas Sanfilippo answer questions about the multidisciplinary approach to care during the CURE Educated Patient Skin Cancer Summit.

Early-Phase Trial Assessing Novel CAR-T Cell Therapy in a Type of Blood Cancer Terminated

July 12th 2022

The manufacturer of the novel CAR-T cell therapy announced it terminated an early-phase trial investigating the treatment’s efficacy after there was a lack of benefit in patients with relapsed or refractory T-cell lymphoma, a type of blood cancer.

Study of Novel Drug Combo in Head and Neck Cancer Closed After Several Patient Deaths

July 12th 2022

A clinical trial reviewing the safety and efficacy of a treatment regimen of enoblituzumab in combination with either retifanlimab or tebotelimab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck has been stopped by the manufacturer of the cancer drugs.

Rejoining the Kingdom of the Well After Cancer

July 12th 2022

After cancer, my “normal” life is long forgotten, but how can I get back to life as a person who is well?

I Need to Address the Elephant in the Room: Cancer

July 12th 2022

Heartbreak and loss trail behind us every day in the cancer world. But so does understanding, friendship and love.

Educated Patient® Skin Cancer Summit Radiation Presentation: June 18, 2022

July 12th 2022

Watch Dr. Nicholas Sanfilippo, from Weill Cornell Medicine, discuss radiation therapy options during the CURE Educated Patient Skin Cancer Summit.

FDA to Expedite Review of Novel Drug to Treat Common Side Effect of Cancer

July 11th 2022

The FDA granted abelacimab a fast track designation for the treatment of thrombosis, a common and sometimes deadly type of blood clot associated with cancer.

Study Launches to Investigate Effectiveness of Potential First-in-Class Lung Cancer Drug

July 11th 2022

The first patient was dosed in a phase 2 trial studying the efficacy of sapanisertib in patients with NRF2-mutant relapsed/refractory lung cancer.

Diet Was One Thing I Was Able to Control When Facing Cancer

July 11th 2022

After being diagnosed with cancer, I took a hard look at what I was eating and made some positive changes.

In Recent Decades, Immunotherapy Extended Advanced Melanoma Survival from Months to Years

July 11th 2022

Thanks to the FDA approval of immunotherapy agents, the average survival for patients for stage 4 melanoma has drastically increased over the past 20 years, an expert explained.

Educated Patient® Skin Cancer Summit Surgery Presentation: June 18, 2022

July 11th 2022

Watch Dr. Erica B. Friedman, from NYU Grossman School of Medicine, discuss surgery, during the CURE Educated Patient Skin Cancer Summit.

Educated Patient® Skin Cancer Summit Topical Treatments Presentation: June 18, 2022

July 10th 2022

Watch Dr. Sherrif Ibrahim, from the University of Rochester Medical Center, discuss topical treatments during the CURE Educated Patient Skin Cancer Summit.

Educated Patient® Skin Cancer Summit The Basics Panel: June 18, 2022

July 9th 2022

Watch Dr. Barbara Ma, Dr. Evan Lipson, Dr. Sunandana Chandra and Samantha Guild answer questions on the basics of skin cancer and melanoma during the CURE Educated Patient Skin Cancer Summit.

‘I Want to Die With This, Not Because of It,’ Says Survivor of Rare Blood Cancer

July 8th 2022

Kerry Fraser, a survivor of a myeloproliferative neoplasm and retired NHL referee, explained how he came to be diagnosed, and his hopes for the future of the group of rare blood cancers.

FDA’s Approval of Breyanzi Gives Some Patients With Lymphoma a ‘Life-Saving Therapy', Says Expert

July 8th 2022

The FDA approval of Breyanzi, a novel CAR-T cell therapy, provides many patients with lymphoma a new treatment option that can be used earlier in the course of their disease, according to an expert.

I'm a 'Cancer Long-Hauler'

July 8th 2022

I typically don’t use cancer labels, such as “survivor” or “thriver,” but when I heard about COVID-19 “long-haulers,” the term resonated with me.

Novel Breast Cancer Drug Meets Main Goal of Eliciting Treatment Responses

July 8th 2022

Treatment with praluzatamab ravtansine improved outcomes in some patients with breast cancer, though one expert noted further study of the drug is needed.